Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Key Points

• Chugai Pharmaceutical Co., Ltd. experienced a 1,340.3% increase in short interest from July 15 to July 31, reaching a total of 110,900 shares.
• The company's stock price is currently at $20.79, with a market capitalization of $68.42 billion and a PE ratio of 26.32.
• Chugai reported quarterly earnings of $0.20 EPS with revenues of $2.01 billion for the last quarter.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 110,900 shares, anincreaseof1,340.3% from the July 15th total of 7,700 shares. Currently,0.0% of the shares of the company are sold short. Based on an average trading volume of 485,800 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 485,800 shares, the short-interest ratio is currently 0.2 days. Currently,0.0% of the shares of the company are sold short.

Chugai Pharmaceutical Stock Performance

CHGCY stock traded down $0.27 during mid-day trading on Thursday, hitting $20.79. The company had a trading volume of 107,378 shares, compared to its average volume of 204,237. The stock's fifty day moving average price is $24.38 and its two-hundred day moving average price is $24.65. Chugai Pharmaceutical has a 12 month low of $19.50 and a 12 month high of $31.26. The firm has a market cap of $68.42 billion, a PE ratio of 26.32 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The company had revenue of $2.01 billion for the quarter. Equities analysts anticipate that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.